5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety Alan K. Davis PhD, Sara So MS, Rafael Lancelotta MS, Joseph P. Barsuglia PhD, Roland R. Griffiths PhD The American Journal of Drug and Alcohol Abuse, 2018 DOI: 10.1080/00952990.2018.1545024 Abstract Background : A recent epidemiological study suggested that 5-methoxy-N,Ndimethyltryptamine (5-MeO-DMT) used for spiritual and recreational reasons is associated with subjective improvement in depression and anxiety. Further exploration of the potential psychotherapeutic effects of 5-MeO-DMT could inform future clinical trials. Objectives : We examined self-reported improvement in depression and anxiety among people who use 5-MeODMT in a group setting with [...]
Lire la suiteAnxiety, panic, and hopelessness during and after ritual ayahuasca intake in a woman with generalized anxiety disorder : A case report Rafael G. DOS SANTOS, Flavia L. OSÓRIO, José Alexandre S. CRIPPA and Jaime E. C. HALLAK Journal of Psychedelic Studies, 2017, 1, (1), pp. 35–39 DOI: 10.1556/2054.01.2017.004 Background and aims : Ayahuasca is a dimethyltryptamine- and β-carboline-rich hallucinogenic beverage traditionally used by indigenous groups of Northwest Amazonian for ritual and therapeutic purposes. Animal and human studies suggest that ayahuasca has antidepressant and anxiolytic potentials and has a good safety profile. However, anxiety-like reactions may also occur after ayahuasca intake, although they are rare. Methods [...]
Lire la suitePsychedelic drugs in the treatment of anxiety, depression and addiction Tor-Morten Kvam, Lowan H. Stewart & Ole A. Andreassen Tidsskriftet, Den Norske Legeforening, November 2018 https://www.researchgate.net/publication/332136512 B A C K G R O U N D There is growing interest in the use of psychedelic drugs for the treatment of mental disorders. The drugs are considered safe when administered within a clinical framework. Older studies performed prior to 1970 had methodological shortcomings, but studies in recent years have shown promising results regarding the use of psychedelic drugs in unipolar depression, depression in life-threatening illness, anxiety and addiction. The aim of this literature review is to [...]
Lire la suiteThe Divergent Effects of CDPPB and Cannabidiol on Fear Extinction and Anxiety in a Predator Scent Stress Model of PTSD in Rats John Shallcross, Peter Hámor, Allison R. Bechard, Madison Romano, Lori Knackstedt and Marek Schwendt Frontiers in Behavioral Neuroscience, May 2019 | Volume 13 | Article 91 ORIGINAL RESEARCH published: 10 May 2019 doi: 10.3389/fnbeh.2019.00091 Post-traumatic stress disorder (PTSD) currently has no FDA-approved treatments that reduce symptoms in the majority of patients. The ability to extinguish fear memory associations is impaired in PTSD individuals. As such, the development of extinction-enhancing pharmacological agents to be used in combination with exposure therapies may benefit the treatment of [...]
Lire la suiteBrain Imaging Studies on the Cognitive, Pharmacological and Neurobiological Effects of Cannabis in Humans : Evidence from Studies of Adult Users. Aviv Weinstein, Abigail Livny, Abraham Weizman. Current Pharmaceutical Design, 2016, 22, 42, 6366-6379. doi: 10.2174/1381612822666160822151323. PMID : 27549374 Abstract Cannabis is the most widely used illicit drug worldwide. Regular cannabis use has been associated with a range of acute and chronic mental health problems, such as anxiety, depression, psychotic symptoms and neurocognitive impairments and their neural mechanisms need to be examined. This review summarizes and critically evaluates brain-imaging studies of cannabis in recreational and regular cannabis users between January 2000 and January 2016. The [...]
Lire la suiteAwareness of Emotional Expressions in Cannabis Users : An Event-Related Potential Study Robert D. Torrence, Donald C. Rojas and Lucy J. Troup Frontiers in Psychology, February 2019 | Volume 10 | Article 69 ORIGINAL RESEARCH doi: 10.3389/fpsyg.2019.00069 Abstract Cannabis use has been associated with anxiogenic effects when used in low frequency for a short duration, but cannabis can also have anxiogenic effects when used heavily for a long duration. Animal studies have indicated the neurobiological mechanisms related to cannabis and anxiety; however, research has been limited on the related neurocognitive mechanisms. Previous research has indicated that cannabis use is associated with alterations in event-related potentials (ERPs). [...]
Lire la suiteDynamical exploration of the repertoire of brain networks at rest is modulated by psilocybin Louis-David Lord, Paul Expert, Selen Atasoy, Leor Roseman, Kristina Rapuano, Renaud Lambiotte, David J. Nutt, Gustavo Deco, Robin L. Carhart-Harris, Morten L. Kringelbach, Joana Cabral, NeuroImage, 2019, 199, 127–142 https://doi.org/10.1016/j.neuroimage.2019.05.060 A B S T R A C T Growing evidence from the dynamical analysis of functional neuroimaging data suggests that brain function can be understood as the exploration of a repertoire of metastable connectivity patterns (‘functional brain networks’), which potentially underlie different mental processes. The present study characterizes how the brain's dynamical exploration of resting-state networks is rapidly modulated by intravenous [...]
Lire la suitePilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction Matthew W Johnson, Albert Garcia-Romeu, Mary P Cosimano and Roland R Griffiths Journal of Psychopharmacology, 2014, Vol. 28(11) 983–992 © The Author(s) 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/0269881114548296 Abstract Despite suggestive early findings on the therapeutic use of hallucinogens in the treatment of substance use disorders, rigorous follow-up has not been conducted. To determine the safety and feasibility of psilocybin as an adjunct to tobacco smoking cessation treatment we conducted an openlabel pilot study administering moderate (20 mg/70 kg) and high (30 mg/70 kg) doses of psilocybin within a structured 15-week smoking cessation treatment [...]
Lire la suiteThe Cannabis Conundrum : Thinking Outside the THC Box Sarah L. Hagerty, Sophie L. York Williams, Vijay A. Mittal, and Kent E. Hutchison The Journal of Clinical Pharmacology, 2015, 55, 8, 839–841 DOI: 10.1002/jcph.511 Keywords : cannabis, cannabinoids, D9-tetrahydrocannabinol (THC), cannabidiol (CBD), psychosis Despite nationwide movements to legalize and regulate cannabis, our understanding of its effects on human health is tenuous at best. Developing a solid evidence base regarding the health effects of cannabis is imperative given the momentum for legalization and the demand for sound regulatory practices. This present commentary will identify limitations with respect to previous research on cannabis, discuss the genesis and implications [...]
Lire la suiteCannabis For Cancer-Related Symptoms (CAFCARS) https://clinicaltrials.gov/ct2/show/NCT03948074?recrs=abdf&cond=cannabis&draw=2&rank=98 ClinicalTrials.gov Identifier: NCT03948074 Recruitment Status : Not yet recruiting First Posted : May 13, 2019 Last Update Posted : May 13, 2019 See Contacts and Locations Sponsor: Pippa Hawley Information provided by (Responsible Party): Pippa Hawley, British Columbia Cancer Agency Study Description Brief Summary: Clinical evidence is urgently needed to be able to advise patients on which cannabis-based products to take, or to avoid, in managing cancer-related symptoms. This trial was therefore designed to determine which cannabis extract combination (High THC-Low CBD, Low THC-High CBD, or Equal amounts of THC and CBD) is most effective at treating cancer related symptoms for each [...]
Lire la suite